Literature DB >> 24022527

Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?

Angelita Habr-Gama1, Jorge Sabbaga, Joaquim Gama-Rodrigues, Guilherme P São Julião, Igor Proscurshim, Patricia Bailão Aguilar, Wladimir Nadalin, Rodrigo O Perez.   

Abstract

BACKGROUND: No immediate surgery (Watch and Wait) has been considered in select patients with complete clinical response after neoadjuvant chemoradiation to avoid postoperative morbidity and functional disorders after radical surgery.
OBJECTIVE: The purpose of this study was to demonstrate the long-term results of patients who had a complete clinical response following an alternative chemoradiation regimen and were managed nonoperatively.
DESIGN: This is a prospective study. SETTINGS: This study was conducted at a single center. PATIENTS: Seventy consecutive patients with T2-4N0-2M0 distal rectal cancer were studied. Neoadjuvant chemoradiotherapy included 54 Gy and 5-fluorouracil/leucovorin delivered in 6 cycles every 21 days. Patients were assessed for tumor response at 10 weeks from radiation completion. Patients with incomplete clinical response were referred to immediate surgery. Patients with complete clinical response were not immediately operated on and were monitored. MAIN OUTCOME MEASURES: The primary outcomes measured were the initial complete clinical response rates after 10 weeks and the sustained complete clinical response rates after 12 months from chemoradiotherapy.
RESULTS: One patient died during chemoradiotherapy because of cardiac complications. Forty-seven (68%) patients had initial complete clinical response. Of these, 8 developed local regrowth within the first 12 months of follow-up (17%). Thirty-nine sustained complete clinical response at a median follow-up of 56 months (57%). An additional 4 patients (10%) developed late local recurrences (>12 months of follow-up). Overall, 35 patients never underwent surgery (50%). LIMITATIONS: This study is limited by the short follow-up and small sample size.
CONCLUSION: Extended chemoradiation therapy with additional chemotherapy cycles and 54 Gy of radiation may result in over 50% of sustained (>12 months) complete clinical response rates that may ultimately avoid radical rectal resection. Local failures occur more frequently during the initial 12 months of follow-up in up to 17% of cases, whereas late recurrences are less common but still possible, leading to 50% of patients who never required surgery. Strict follow-up may allow salvage therapy in the majority of these patients (see Video, Supplemental Digital Content 1, http://links.lww.com/DCR/A113.).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24022527     DOI: 10.1097/DCR.0b013e3182a25c4e

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  98 in total

1.  "Watch and wait" approach in rectal cancer patients following complete clinical response to neoadjuvant chemoradiotherapy does not compromise oncologic outcomes.

Authors:  Gürel Neşşar; Ali Eba Demirbağ; Hasan Cem Mısırlıoğlu; Semih Sezer
Journal:  Turk J Gastroenterol       Date:  2019-11       Impact factor: 1.852

2.  Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms.

Authors:  G Rizzo; D P Pafundi; F Sionne; L D'Agostino; G Pietricola; M A Gambacorta; V Valentini; C Coco
Journal:  Tech Coloproctol       Date:  2021-01-18       Impact factor: 3.781

3.  Rectal cancer: is 'watch and wait' a safe option for rectal cancer?

Authors:  Bruce D Minsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-22       Impact factor: 46.802

4.  Intravoxel Incoherent Motion-derived Histogram Metrics for Assessment of Response after Combined Chemotherapy and Radiation Therapy in Rectal Cancer: Initial Experience and Comparison between Single-Section and Volumetric Analyses.

Authors:  Stephanie Nougaret; Hebert Alberto Vargas; Yulia Lakhman; Romain Sudre; Richard K G Do; Frederic Bibeau; David Azria; Eric Assenat; Nicolas Molinari; Marie-Ange Pierredon; Philippe Rouanet; Boris Guiu
Journal:  Radiology       Date:  2016-02-26       Impact factor: 11.105

Review 5.  The Perfect Total Mesorectal Excision Obviates the Need for Anything Else in the Management of Most Rectal Cancers.

Authors:  Richard John Heald; Ines Santiago; Oriol Pares; Carlos Carvalho; Nuno Figueiredo
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 6.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 7.  Organ-Preserving Strategies for the Management of Near-Complete Responses in Rectal Cancer after Neoadjuvant Chemoradiation.

Authors:  Patricio B Lynn; Paul Strombom; Julio Garcia-Aguilar
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

8.  Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review.

Authors:  K C Wilson; M P Flood; D Oh; N Calvin; M Michael; R G Ramsay; A G Heriot
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

9.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

10.  Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Authors:  Clotilde Debove; Nathalie Guedj; Ecoline Tribillon; Léon Maggiori; Magaly Zappa; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2016-03-07       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.